Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Alexion Pharmaceuticals Inc (ALXN) USD0.0001

Sell:$122.04 Buy:$122.11 Change: $0.04 (0.03%)
NASDAQ:1.28%
Market closed |  Prices as at close on 1 December 2020 | Switch to live prices |
Sell:$122.04
Buy:$122.11
Change: $0.04 (0.03%)
Market closed |  Prices as at close on 1 December 2020 | Switch to live prices |
Sell:$122.04
Buy:$122.11
Change: $0.04 (0.03%)
Market closed |  Prices as at close on 1 December 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

Contact details

Address:
121 Seaport Blvd
BOSTON
02210-2050
United States
Telephone:
+1 (475) 2302596
Website:
https://alexion.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALXN
ISIN:
US0153511094
Market cap:
$27.10 billion
Shares in issue:
218.85 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Brennan
    Independent Chairman of the Board
  • Ludwig Hantson
    Chief Executive Officer, Director
  • Aradhana Sarin
    Executive Vice President, Chief Financial Officer
  • Indrani Franchini
    Executive Vice President, Chief Compliance Officer
  • Ellen Chiniara
    Executive Vice President, Chief Legal Officer. Corporate Secretary
  • Tanisha Carino
    Executive Vice President, Chief Corporate Affairs Officer
  • Brian Goff
    Executive Vice President, Chief Commercial and Global Operations Officer
  • John Orloff
    Executive Vice President, Head of Research and Development
  • Becky Lillie
    Interim Chief Human Experience Officer
  • Uzair Qadeer
    Chief Diversity Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.